Hydrocarbons, C10, aromatics, >1% naphthalene

Endpoint summary

Description of key information

Repeated Dose Oral 90d – NOAEL = 300 mg/Kg bw for rats (similar to OECD TG 408)

Repeated Dose Inhalation 13 weeks – NOAEC > 0.38 mg/L for rats and dogs (similar to OECD TG 413)

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records

Reference

Endpoint:

sub-chronic toxicity: oral

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

1990/10/30-1991/02/27

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: In agreement to OECD guideline 408.

Justification for type of information:

A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.

Reason / purpose for cross-reference:

read-across: supporting information

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)

Qualifier:

equivalent or similar to guideline

Guideline:

EPA OPP 82-1 (90-Day Oral Toxicity)

GLP compliance:

yes

Limit test:

no

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
Source: Harlan Sprague Dawley Inc.
Sex: Male (50), Female (50)
Age at study initiation: Approximately 8 weeks
Weight at study initiation: Males: 253.0 - 328.4 g; Females: 172.3 - 229.1 g
Housing: Individually
Diet (e.g. ad libitum): Purina Certified Rodent Chow 5002, ad libitum
Water (e.g. ad libitum): Automatic watering system, ad libitum
Acclimation period: 29d

ENVIRONMENTAL CONDITIONS
Temperature (°F): 68-76
Humidity (%): 40-70%
Photoperiod (hrs dark / hrs light): 12/12

Route of administration:

oral: gavage

Vehicle:

corn oil

Details on oral exposure:

The test mixture was administered by oral gavage at a dose of 0, 300, 600, or 1000 mg/ kg at a volume of 2.4 ml/kg, 7 days per week for a period of at least 13 weeks. The control animals received a carrier (corn oil) dose 2.4 ml/kg. The satellite group was dosed at 1000 mg/ kg, 7 days/week for ~13 weeks and was then observed for reversibility, persistence or delayed occurrence of toxic effects for 28 days post-treatment. The amount of test material administered to each animal was recalculated weekly, based on the most recent body weight.

Duration of treatment / exposure:

once daily

Frequency of treatment:

7 days/week for ~13 weeks

Remarks:

Doses / Concentrations:
0, 300, 600, or 1000 mg/ kg
Basis:
other: oral gavage

No. of animals per sex per dose:

Males (10). Females (10) per dose group.

Control animals:

yes, concurrent vehicle

Details on study design:

The test mixture was administered by oral gavage at a dose of 300, 600, or 1000 mg/ kg at a volume of 2.4 ml/kg, 7 days per week for a period of at least 13 weeks. The control animals received a carrier (corn oil) dose 2.4 ml/kg. The satellite group was dosed at 1000 mg/ kg, 7 days/week for ~13 weeks and was then observed for reversibility, persistence or delayed occurrence of toxic effects for 28 days post-treatment. The amount of test material administered to each animal was recalculated weekly, based on the most recent body weight.

The animals were checked for viability twice daily on Monday through Friday, and once daily on Saturday and Sunday. Clinical observations were made daily for toxicological signs. Body weights were recorded prior to dosing and then once a week thereafter. Body weights were also recorded at the scheduled sacrifice at the death of animals that succumbed before the end of the study. Clinical laboratory studies (hematology and serum chemistry) were performed on all animals at main study termination or at the termination of the satellite/recovery study. Blood samples were collected under methoxyflurane anesthesia from the orbital sinus.

Positive control:

none

Observations and examinations performed and frequency:

The animals were checked for viability twice daily on Monday through Friday, and once daily on Saturday and Sunday. Clinical observations were made daily for toxicological signs. Body weights were recorded prior to dosing and then once a week thereafter. Body weights were also recorded at the scheduled sacrifice at the death of animals that succumbed before the end of the study. Clinical laboratory studies (hematology and serum chemistry) were performed on all animals at main study termination or at the termination of the satellite/recovery study. Blood samples were collected under methoxyflurane anesthesia from the orbital sinus.

Sacrifice and pathology:

The necropsy was performed on all animals. The necropsy examined the external surfaces of the body, all orifices, and the cranial, thoracic, and abdominal cavities and their contents. The ovaries, kidneys, adrenal, liver, and testes were weighed prior to fixation. Preserved tissue from the control and high dose group as well from all animals that were sacrificed moribund or succumbed during the study were processed, sectioned, stained (hematoxylin and eosin) and examined microscopically. Abnormalities from the low and mid doses were examined as well as the stomach, spleen, urinary bladder, and the thyroid.

Other examinations:

HEMATOLOGY
-erythrocyte count
-hematocrit
-hemoglobin
-leukocyte count (total and differential)
-mean corpuscular volume
-mean corpuscular hemoglobin
-mean corpuscular hemoglobin conc.
-platelets

SERUM CHEMISTRY
-total bilirubin
-albumin
-blood urea nitrogen
-calcium
-cholesterol
-creatinine
-electrolytes (Na, K, Cl)
-glucose
-total protein
-triglycerides
-phosphorous
-gamma glutamyl transferase
-serum aspartate aminotransferase
-serum alanine aminotransferase

Statistics:

The following parameters were statistically analyzed:
-mean hematology parameters
-mean serum chemistry parameters
-mean organ weights
-mean organ to body weights, by weighing period
-mean food consumption

Comparisons were limited to within sex analysis. Variance was assessed through the use of a one way ANOVA. Bartlett’s test (conducted at the 1% level of significance) was performed to determine if the dose groups had equal variance. If the variances were equal, the test was done using parametric methods, otherwise nonparametric techniques were used.

The parametric procedures used a one way ANOVA using the F distribution to assess significance. If significant differences among the means were indicated, Dunnett’s test was used to determine which treatment groups differ significantly from control. In addition, a regression analysis for linear response in the dose group was performed.

The nonparametric procedures tested for the equality of means using the Kruskal-Walls test. If significant differences were indicated, Dunn’s Summed Rank test was used to determine which treatment group differed significantly from control. Jonckheere’s test for monotonic trend in the dose response was performed.

Bartlett’s test was conducted at the 1% level of significance. All other tests were conducted at the 5% and 1% level of significance.

The t-test was used to compare the satellite group’s main study termination and recovery termination hematology and clinical chemistry values. The t-test was also used to compare the satellite and the control groups’ organ weights. The t-test was also used to compare the high dose and satellite groups to ensure similar results in order to accurately evaluate the recovery effects.

Clinical signs:

effects observed, treatment-related

Mortality:

mortality observed, treatment-related

Body weight and weight changes:

effects observed, treatment-related

Food consumption and compound intake (if feeding study):

effects observed, treatment-related

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

no effects observed

Haematological findings:

effects observed, treatment-related

Clinical biochemistry findings:

effects observed, treatment-related

Urinalysis findings:

not specified

Behaviour (functional findings):

not specified

Organ weight findings including organ / body weight ratios:

effects observed, treatment-related

Gross pathological findings:

effects observed, treatment-related

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Histopathological findings: neoplastic:

no effects observed

Details on results:

CLINICAL SIGNS and MORTALITY
There were a total of 10 animal deaths; four were attributed to dosing trauma or aspiration of the test material. Two animals (1 female at 300 mg/kg and a female in the satellite group) died of unknown causes. The four remaining deaths (1 male, 3 female) at the 1000 mg/kg dose appeared to be treatment-related. Animals in the 0, 300, or 600 mg/kg dose displayed little to no clinical signs. Animals in the 1000 mg/kg dose consistently displayed signs of ano-genital staining, alopecia, and emaciation. Note: The animals in the 1000mg/kg dose were initially treated with a dose of 1200 mg/kg, but displayed severe signs of hypothermia and hypoactivity and after day 3, their dose was reduced to 1000mg/kg. Sporadic clinical signs across all groups included oral discharge, red discharge from the eyes, rales, sores, scabs, soft stool, and little sign of stool.

BODY WEIGHT and WEIGHT GAIN
Statistically significant decreases in body weight for males at the 1000 mg/kg dose were noted in all intervals from day 7 through termination. There were no noted differences in any of the female groups.

FOOD CONSUMPTION
Food consumption for males at the 1000 mg/kg dose was decreased for week 1 when compared to controls. Food consumption was significantly higher for males at the 600 mg/kg dose at weeks 10-13. Food consumption was significantly higher for females at the 600 and 1000 mg/kg dose at weeks 7-10.

HAEMATOLOGY
Non-biologically relevant but statistically significant decreases were noted in:
-Hematocrit: Males at 300, 600, and 1000 mg/kg doses; Females at 600 mg/kg dose. There is no dose response for male rats. The hematocrit count was statistically affected at all does levels; however, all treated male rats had hematocrit counts that were 95% control. Hematocrit counts were only statistically affected for the female rats at 600 mg/kg (96% of control). Hematocrit counts were not different from controls in the recovery group that was initially dosed with 1000 mg/kg/day. Hematocrit levels returned to normal in the recovery group (initially dosed with 1000 mg/kg). Since only the male rats were statistically affected, no dose response was observed, and experimental values were within 10% of controls (normal physiological range), these changes are not considered to be an adverse effect.
-Hemoglobin: Males at 300, 600, and 1000 mg/kg doses: Females 600, and 1000 mg/kg dose. Male rats exposed to 300, 600, and 1000 mg/kg had decreased hemoglobin counts of 95%, 95%, and 92.5% of control, respectively. Female rat hemoglobin was 93% of control at the 600 and 1000 mg/kg doses. Hemoglobin concentrations returned to normal in the recovery group (initially dosed with 1000 mg/kg). Since no dose response was observed in either the male or female rats, and experimental values were within 10% of controls (normal physiological range), these changes are not considered to be an adverse effect.
-Mean corpuscular hemoglobin concentration (MCHC): Males at 300, 600, and 1000 mg/kg doses: Females 600, and 1000 mg/kg dose. Only male rats in the 1000 mg/kg were statistically affected, however, the MCHC level was 97.5% of control. Female rats were statistically affected at all doses, however, no dose response was observed. The values (% control) for MCHC were 96.7%, 96.9%, 96% for the 300, 600, and 1000 mg/kg treated female rats respectively. MCHC levels returned to normal in the recovery group (initially dosed with 1000 mg/kg). Since only the female rats were statistically affected, no dose response was observed, and experimental values were within 10% of controls (normal physiological range), these changes are not considered to be an adverse effect.
- Bone Marrow – There were no adverse pathology findings of the bone marrow in any animal at any dose.
- RBC– Only male rats in the 600 and 1000 mg/kg were statistically affected. The values for RBC (% control) were 95% and 91.5% for the 600 and 1000 mg/kg groups, respectively. Female rats RBC were not significantly decreased at any test dose. RBC levels returned to normal in the recovery group (initially dosed with 1000 mg/kg). Conclusion: Since only the male rats have a significant decrease in RBC counts, it is unlikely that this change is an adverse effect or is related to the splenic hemosiderosis observed in both sexes of rats. The decrease observed in the male rats was less than 10% of control (normal physiological range) and these changes are not considered to be an adverse effect.

The hematology for the recovery period revealed a recovery trend for all of the observed decreased parameters; including a significant change in the red blood cells, hemoglobin, MCHC for both males and females.

CLINICAL CHEMISTRY
Statistically significant increases were noted in mean serum chemistry values in:
-Albumin: Females at 600 and 1000 mg/kg doses
-Creatinine: Females at 1000 mg/kg doses
-Potassium: Males at 1000 mg/kg doses
-Total Protein: Females at 600 and 1000 mg/kg doses
-Cholesterol: Females at 600 and 1000 mg/kg doses
Sporadic, statistically significant increases were also noted in albumin (males) and transferase (females) and significant decreases were noted in chloride (females) and triglycerides (males).

ORGAN WEIGHT
There was a statistically significant increase in male liver weight (600 mg/kg) and in male kidney weight (300 and 600 mg/kg). Females demonstrated a significant dose related increase in both liver and kidney weight. The relative organ weights for the recovery period revealed a recovery trend in the liver and testes.

GROSS PATHOLOGY and HISTOPATHOLOY
The most frequently noted abnormalities in surviving animals were cervical lymph node redness, abnormal small/large intestine contents, small/large intestine distention, staining of the fur, alopecia, and eye damage from eye bleeding. The most frequent abnormalities for the animals which succumbed prior to study termination were: thickened liver, small spleen, enlarged adrenals, staining of fur, emaciation, abnormal stomach/small/large intestine contents, stomach distension, and stomach mucosa thinner than normal.

Treatment related changes were noted in the livers of the females of all dosage groups consisting of centrilobular hepatocellular hypertrophy. These liver changes were noted at a sporadic and lower incidence in male rats. Hepatocellular hypertrophy was not observed in the satellite group that was allowed to recover. A dose related increase amount of brown pigment (hemosiderin) in macrophages in the splenic red pulp was observed in all animals that received 600 and 1000 mg/kg doses. This hemosiderin material was still present after recovery, but was reduced. An increased incidence of minimal to moderate hyperplasia and hypertrophy of the thyroid follicular epithelial cells was noted in all male animal dosage groups and in females exposed to 600 and 1000 mg/kg. These effects were reversed in the recovery group. In response to xenobiotics, there is a greater predisposition towards proliferate lesions (e.g. hyperplasia) of follicular cells in laboratory rodents, especially males, than in the human thyroid. Capen et al. Toxicol Pathol 1989; 17:266 as cited in Werner and Ingbar’s The Thyroid. 7th ed. Braverman and Utiger. 1991. Since these effects were reversible in the recovery group and due to the rodent specific response, this effect at the lower dose is deemed to be an adaptive response.

Recovery Group:
The relative organ weight, clinical chemistry and hematology data indicated recovery during the 28-day post exposure period. The satellite group values were similar to control values.

Liver and thyroid changes seen at termination appeared to be reversible as they were not observed in the satellite group after the 28-day recovery period. The changes seen in the spleen, urinary bladder and stomach in the main study termination were at a lower incidence and/or severity in the satellite group after the 28-day recovery period also indicating reversibility. The hematology, serum chemistry and relative organ weights also indicated reversibility of the effects.

Key result

Dose descriptor:

NOAEL

Effect level:

300 mg/kg bw/day (actual dose received)

Sex:

male/female

Basis for effect level:

other: Mortality observed at the highest dose tested. Food consumption was higher at the 600 and 1000 mg/kg doses in both sexes. Clinical chemistry and haematology parameters were affected at the 600 and 1000 mg/kg doses in both sexes.

Critical effects observed:

not specified

Conclusions:

The NOAEL for MRD-90-884 is 300 mg/kg body weight under the test conditions of this study.

Executive summary:

A 90-day subchronic study was conducted in rats to assess the toxicity of MRD-90-884. The test mixture was administered by oral gavage at a dose of 0, 300, 600, or 1000 mg/ kg 7 days per week for a period of 13 weeks.  The control animals received a carrier (corn oil) dose and a satellite group was dosed at 1000 mg/ kg, 7 days/week for 13 weeks and was then observed for reversibility, persistence or delayed occurrence of toxic effects for 28 days post-treatment.  Observations were made as to the nature, onset, severity, and duration of toxicological signs. There were a total of 10 animal deaths; four deaths (1 male, 3 female) at the 1000 mg/kg dose were attributed to the treatment.   There was an overall low incidence of clinical signs at the 300 and 600 mg/kg doses.  Low food consumption and emaciation were observed in animals dosed at 1000 mg/kg.  Post mortem examinations revealed a significant increase in liver and kidney weights in male and female animals as well as increase in body weight for all animals except for males in the high dose group.  Organ weight, clinical chemistry, and hematology data from the satellite recovery group indicated recovery during the 28 day recovery period.  Based on the data recorded in this study, the NOAEL for MRD-90-884 is 300 mg/kg.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

NOAEL

300 mg/kg bw/day

Study duration:

subchronic

Species:

rat

Quality of whole database:

Only sub-chronic oral toxicity study available for assessment.

Repeated dose toxicity: inhalation - systemic effects

Link to relevant study records

Reference

Endpoint:

sub-chronic toxicity: inhalation

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Source of data is from peer reviewed literature. Acceptable well-documented study report which meets basic scientific principles: non-GLP.

Justification for type of information:

A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.

Reason / purpose for cross-reference:

read-across: supporting information

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)

GLP compliance:

not specified

Species:

other: Rats and Dogs

Strain:

other: RATS: Harlan Wistar; DOGS: Beagles

Sex:

male

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: RATS: Harlan
-Number: RATS: 25 males; DOGS: 4 males

Route of administration:

inhalation: vapour

Type of inhalation exposure:

whole body

Vehicle:

other: unchanged (no vehicle)

Details on inhalation exposure:

25 rats and four dogs per dose were used.

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

Gas chromatographic analyses of the nominal 0.25, 0.5, and 1.0 mg/liter vapor-air mixtures yielded mean measured concentrations of 0.10, 0.22, and 0.38 mg/liter or 17, 38, and 66 ppm.

Remarks:

Doses / Concentrations:
17, 38, and 66 ppm (0.10, 0.22, 0.38 mg/L)
Basis:
analytical conc.

No. of animals per sex per dose:

RATS: 6 males/dose (25 total); DOGS: 1 male/dose (4 total)

Details on study design:

Methods

Species and number. Twenty-five male rats and four dogs per level were used. Another 20 rats, from the same week of production, were maintained for use as challenge exposure controls (naive rats). The challenge exposures were run to determine whether the 6-hr daily inhalation of a non-lethal level of hydrocarbon, whether by acclimatization or induction of enzymes, would result in the rat becoming more or less resistant than non-exposed or naive controls from the same lot of animals.

Concentrations. A control group (exposed to dilution air) plus groups exposed to three graded levels of test material were utilized for each compound.

Duration. Exposures were 6 hr/day, 5 days/wk for 13 wk.

Observations. Once each week, body weights of both species and food consumption for dogs were determined. Overall appearance and behavior were checked daily.

Procedure. At 3, 8, and 13 wk of exposure three, three, and four rats, respectively, from each group, including controls, were sacrificed. After 13 wk of exposure 10 surviving rats from each group and 20 unexposed rats of the same age were used to detect any significant differences in time to death or in occurrence of signs of distress among the groups. The groups were “challenged” simultaneously by exposure to a vapor air concentration 1.25-2 times the 4-hr rat LC50 until 25 % of the group succumbed or for no more than a 6-hr period. The remaining rats, or those surviving the subacute exposure, exclusive of the ten per level reserved for the challenge exposure were sacrificed after 13 wk and tissues were taken for histopathological interpretation following gross autopsy. The assignment of rats to each of the above groups was made by random selection before the start of the study.

Clinical and hematological schemata. These tests were performed on all dogs initially and prior to sacrifice; and on rats, prior to sacrifice at 3, 8, and 13 wk of exposure. Minimum hematological evaluation for each animal included hematocrit, total erythrocyte count, reticulocyte count, and total and differential leucocyte counts. The biochemical survey included serum alkaline phosphatase, serum glutamic oxoacetic transaminase, serum glutamic pyruvic transaminase, and blood-urea-nitrogen on the rats, and these tests plus bilirubin and blood glucose on the dogs. Initial pre-terminal electrocardiograms were performed on all dogs. Urinalyses were conduct with both species.

Autopsy and pathology schemata. Gross examinations were made of all organ system Histopathological examination included brain (three sections), respiratory (three sections minimum, based on acute exposure data results), heart, thyroid, live kidney, adrenal, spleen, pancreas, stomach and intestines, skeletal muscle, bat marrow, and peripheral nerves. The reproductive organs and eyes were not scheduled for histopathological study unless abnormalities were discovered upon gross examination. Tissues were taken from all dogs and from rats sacrificed after 3, 8, and 13 wk of inhalation of the vapor.

Observations and examinations performed and frequency:

Observations. Once each week, body weights of both species and food consumption for dogs were determined. Overall appearance and behavior were checked daily.

Clinical and hematological schemata. These tests were performed on all dogs initially and prior to sacrifice; and on rats, prior to sacrifice at 3, 8, and 13 wk of exposure. Minimum hematological evaluation for each animal included hematocrit, total erythrocyte count, reticulocyte count, and total and differential leucocyte counts. The biochemical survey included serum alkaline phosphatase, serum glutamic oxoacetic transaminase, serum glutamic pyruvic transaminase, and blood-urea-nitrogen on the rats, and these tests plus bilirubin and blood glucose on the dogs. Initial pre-terminal electrocardiograms were performed on all dogs. Urinalyses were conduct with both species.

Sacrifice and pathology:

Autopsy and pathology schemata. Gross examinations were made of all organ system. Histopathological examination included brain (three sections), respiratory tract (three sections minimum, based on acute exposure data results), heart, thyroid, live kidney, adrenal, spleen, pancreas, stomach and intestines, skeletal muscle, bone marrow, and peripheral nerves. The reproductive organs and eyes were not scheduled for histopathological study unless abnormalities were discovered upon gross examination. Tissues were taken from all dogs and from rats sacrificed after 3, 8, and 13 wk of inhalation of the vapor.

Statistics:

Statistical analysis. Based on mortality during a 14-day observation period, the most probable LC50 with its fiducial range was calculated by the Thompson method of moving averages using tables by Weil (1952) and other unpublished tables. The results of the quantitative continuous variables, such as body weight changes, were intercompared for the dosage groups and the controls by the use of the following tests: Bartlett’s homogeneity of variance, analysis of variance, rank sum, and Duncan’s multiple range. The latter was used, if F for analysis of variance was significantly high, to delineate which groups differed from the controls. If Bartlett’s test indicated heterogeneous variances, the F test was used for each group versus the control. If these individual F tests were not significant, Student’s t test was used; if significant, the means were compared by the Cochran t test or the rank sum test. Frequency data, such as incidences of mortality or of micro-pathological conditions, were intercompared by the normal deviate of chi square calculated with Yates’ correction for continuity. In all cases the fiducial limit of 0.05 was employed to delineate the critical level of significance.
In general, only criteria that differed statistically significantly from the control group are discussed. Omission of comment is indicative that no valid differences were found. An attempt has been made to round off machine calculated data but if it is obvious that the data portend fictitious accuracy the implication should be ignored.

Clinical signs:

no effects observed

Mortality:

no mortality observed

Body weight and weight changes:

no effects observed

Food consumption and compound intake (if feeding study):

not examined

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

no effects observed

Haematological findings:

no effects observed

Clinical biochemistry findings:

no effects observed

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Organ weight findings including organ / body weight ratios:

no effects observed

Gross pathological findings:

no effects observed

Histopathological findings: non-neoplastic:

not examined

Histopathological findings: neoplastic:

not examined

Details on results:

RATS. One rat at the 0.10-mg/liter level died after 14 days. Death was attributed to a pneumonic infection as evidenced by extensive lung abscesses. None of the observations were dosage-related and are discounted for that reason.
Significant findings (Rats) - Concentration (mg/liter)
Specific gravity urine, 9 weeks, rats - 0.38 mg/liter - Not dosage-related;
Blood urea nitrogen, 3 weeks, rats 0.10 mg/liter - Not dosage related;
Red blood cell count, Packed cell volume, and Hemoglobin, 9 weeks, rats 0.38 mg/liter - Not dosage-related
Alkaline phosphatase, 9 weeks, rats 0.10 mg/liter - Not dosage-related;
Neutrophil differential, 13 weeks, rats 0.22 mg/liter - Not dosage-related;
Lymphocyte differential, 13 weeks, rats 0.22 mg/liter - Not dosage-related.

DOGS. Pre-exposure polymorphonuclear neutrophilic leucocytes for the 0.1 mg/liter dogs were slightly higher than the controls on an absolute basis, but on the basis of change from pre-exposure after 13 weeks of inhalation, there were no significant differences that were treatment related.

Key result

Dose descriptor:

NOAEC

Remarks:

Rat

Effect level:

> 0.38 mg/L air (analytical)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: Systemic Toxicity

Key result

Dose descriptor:

NOAEC

Remarks:

Dog

Effect level:

> 0.38 mg/L air (analytical)

Based on:

test mat.

Sex:

male

Basis for effect level:

other: Systemic Toxicity

Critical effects observed:

not specified

Conclusions:

The test material’s NOAEC > 0.38 mg/liter (66 ppm), which was the highest achievable vapor concentration.

Executive summary:

Twenty-five male rats and four dogs per level were exposed for 6 hr/day, 5 days/wk for 13 wk. Another 20 rats, from the same week of production, were maintained for use as challenge exposure controls (naive rats). The challenge exposures were run to determine whether the 6-hr daily inhalation of a non-lethal level of hydrocarbon, would result in the rat becoming more or less resistant. One rat at the 0.10-mg/liter level died after 14 days. Death was attributed to a pneumonic infection as evidenced by extensive lung abscesses. None of the observations were dosage-related and are discounted for that reason. The test material’s NOAEC > 0.38 mg/liter (66 ppm), which was the highest achievable vapor concentration.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

NOAEC

380 mg/m³

Study duration:

subchronic

Species:

other: Rat and Dog

Quality of whole database:

Only sub-chronic inhalation toxicity study available for assessment.

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

There is no repeat dose toxicity data available for Hydrocarbons, C10, aromatics, >1% naphthalene. However, data is available for structural analogues, Hydrocarbons, C10-C13, aromatics, >1% naphthalene andHydrocarbons, C10, aromatics and presented in the dossier. This data is read across to based on analogue read across and a discussion and report on the read across strategy is provided as an attachment in IUCLID Section 13.

Repeat Dose Oral Toxicity

 

Hydrocarbons, C10-C13, aromatics, >1% naphthalene

A 90-day sub chronic study (ExxonMobil, 1991) was conducted in rats to assess the toxicity of the test material (Hydrocarbons, C10-C13, aromatics, >1% naphthalene). The test mixture was administered by oral gavage at a dose of 0, 300, 600, or 1000 mg/Kg 7 days per week for a period of 13 weeks. The control animals received a carrier (corn oil) dose and a satellite group was dosed at 1000 mg/Kg, 7 days/week for 13 weeks and was then observed for reversibility, persistence or delayed occurrence of toxic effects for 28 days post-treatment. Observations were made as to the nature, onset, severity, and duration of toxicological signs. There were a total of 10 animal deaths; four deaths (1 male, 3 female) at the 1000 mg/Kg dose were attributed to the treatment. There was an overall low incidence of clinical signs at the 300 and 600 mg/Kg doses. Low food consumption and emaciation were observed in animals dosed at 1000 mg/Kg. Post mortem examinations revealed a significant increase in liver and kidney weights in male and female animals as well as increase in body weight for all animals except for males in the high dose group. Organ weight, clinical chemistry, and hematology data from the satellite recovery group indicated recovery during the 28 day recovery period. Based on the data recorded in this study, the NOAEL was determined to be 300 mg/Kg.

Additionally, in order to comply with standard information requirements for Annex X substances, an OECD Guideline 90-day sub-chronic (OECD 408) toxicity test is proposed for structural analogue Hydrocarbons, C9-C10, aromatics >1% Naphthalene (EC# 946-365-8). The testing proposal for the same has been presented in the lead registrant dossier for this substance already submitted to ECHA. This study will be conducted subsequent to ECHA's approval and this endpoint will be updated upon completion of the above study. 

 

Repeat Dose Inhalation Toxicity

 

Hydrocarbons, C10, aromatics

In a key sub-chronic inhalation toxicity study (Carpenter et al., 1977), twenty-five male rats and four dogs per level were exposed to the test material (Hydrocarbons, C10, aromatics) for 6 hr/day, 5 days/wk for 13 wk. Another 20 rats, from the same week of production, were maintained for use as challenge exposure controls (naive rats). The challenge exposures were run to determine whether the 6-hr daily inhalation of a non-lethal level of hydrocarbon, would result in the rat becoming more or less resistant. One rat at the 0.10-mg/liter level died after 14 days. Death was attributed to a pneumonic infection as evidenced by extensive lung abscesses. None of the observations were dosage-related and are discounted for that reason. The test material’s NOAEC was determined to be > 0.38 mg/liter (66 ppm), which was the highest achievable vapor concentration.

Justification for classification or non-classification

Based on available read across data, Hydrocarbons, C10, aromatics, >1% naphthalene does not warrant classification as a repeated dose toxicant under Regulation (EC) 1272/2008 on classification, labelling and packaging of substances and mixtures (CLP).